 |
市場調査レポート
商品コード
1321866
癌免疫精密医療の世界市場 (2023-2030年)：エンドユーザー・癌タイプ・治療タイプ・バイオマーカー別の規模・シェア・成長分析・予測Global Precision Immuno-Oncology Market Size, Share, Growth Analysis, By End use, By Cancer type, By Treatment type, By Biomarker - Industry Forecast 2023-2030 |
||||||
| 癌免疫精密医療の世界市場 (2023-2030年)：エンドユーザー・癌タイプ・治療タイプ・バイオマーカー別の規模・シェア・成長分析・予測 |
|
出版日: 2023年07月11日
発行: SkyQuest
ページ情報: 英文 157 Pages
納期: 3～5営業日
|
- 全表示
- 概要
- 目次
世界の癌免疫精密医療の市場規模は、2021年の494億米ドル、2022年の547億4,000万米ドルから、予測期間中は10.8%のCAGRで推移し、2030年には1,243億3,000万米ドルの規模に成長すると予測されています。
世界の癌免疫精密医療は、癌治療における先進的かつ有望な分野であり、癌細胞を標的とし根絶するために精密かつ個別化されたアプローチを活用しています。免疫療法と精密医療を組み合わせることで、この革新的なアプローチは副作用を最小限に抑えながら癌治療の効果を高めることを目指しています。次世代シーケンシングやバイオマーカー解析などの最先端技術は、特定の腫瘍特性を特定し、治療決定を導く上で重要な役割を果たします。現在進行中の研究と臨床試験により、癌免疫精密医療は、癌治療に革命をもたらし、世界中の患者の転帰を改善する大きな可能性を秘めています。
癌の有病率の増加が癌免疫精密医療の需要を促進すると予想されています。癌患者が増加し続ける中、より効果的で的を絞った治療オプションに対するニーズが高まっています。癌免疫精密医療は、特定の腫瘍特性や免疫反応に基づいて個々の患者に合わせた癌治療を行う可能性を提供します。癌と闘うために免疫系の力を活用することで、この新興分野は治療成績を改善し、様々な種類の癌がもたらす課題に対処することが期待されています。
癌免疫精密医療では、化学療法や放射線療法といった従来の癌治療と並行して、併用療法の利用が増加しています。このアプローチは、治療効果を高め、治療抵抗性と闘う可能性があることから人気を得ています。例えば、免疫療法と化学療法の併用は、肺癌やメラノーマのような特定の癌種の治療において有望な結果を示しています。化学療法は腫瘍を縮小させますが、免疫療法は患者の免疫系が癌細胞を認識し、より効果的に攻撃するのを助けます。
当レポートでは、世界の癌免疫精密医療の市場を調査し、市場概要、市場への各種影響因子の分析、技術・イノベーションの動向、法規制環境、市場規模の推移・予測、各種区分・地域別の内訳、競合情勢、主要企業のプロファイルなどをまとめています。
目次
エグゼクティブサマリー
調査手法
親市場の分析
- 市場概要
- 市場規模
- 市場力学
- 促進要因
- 機会
- 抑制要因
- 課題
主要市場洞察
- 技術分析
- 価格分析
- サプライチェーン分析
- バリューチェーン分析
- 市場のエコシステム
- IP分析
- 貿易分析
- スタートアップ分析
- 原材料分析
- イノベーションマトリックス
- パイプライン製品の分析
- マクロ経済指標
- 主要投資分析
- 主要成功要因
- 競合の程度
市場力学と見通し
- 市場力学
- 促進要因
- 機会
- 抑制要因
- 課題
- 規制状況
- ポーターの分析
- 将来のディスラプションに関するSkyquestの特別な洞察
世界の癌免疫精密医療市場：エンドユーザー別
- 市場概要
- 病院
- クリニック
- 研究機関・その他
世界の癌免疫精密医療市場：癌タイプ別
- 市場概要
- 肺癌
- 乳癌
- 前立腺癌
- 黒色腫・その他
世界の癌免疫精密医療市場：治療タイプ別
- 市場概要
- チェックポイント阻害剤
- CAR-T細胞療法
- 癌ワクチン
- その他
世界の癌免疫精密医療市場：バイオマーカー別
- 市場概要
- PD-L1
- BRCA
- KRAS
- EGFR
- その他
世界の癌免疫精密医療市場：地域別
- 市場概要
- 北米
- 欧州
- アジア太平洋
- ラテンアメリカ
- 中東・アフリカ
競合情勢
- トップ5社の比較
- 主要企業の市場での位置付け
- 主要企業の採用戦略
- 主要成功戦略
- 市場における最近の活動
- 主要企業の市場シェア
主要企業プロファイル
- Adaptimmune Therapeutics plc
- Agenus Inc.
- Amgen Inc.
- AstraZeneca plc
- Bristol Myers Squibb Company
- Celgene Corporation
- Eli Lilly and Company
- F. Hoffmann-La Roche Ltd.
- Gilead Sciences, Inc.
- GlaxoSmithKline plc
- Iovance Biotherapeutics, Inc.
- Juno Therapeutics, Inc.
- Kite Pharma, Inc.
- Merck &Co., Inc.
- Neon Therapeutics, Inc.
- Novartis AG
- Pfizer Inc.
- Sanofi SA
- Seattle Genetics, Inc.
- Takeda Pharmaceutical Company Limited
Market Insights
Global Precision Immuno-Oncology Market size was valued at USD 49.4 billion in 2021 and is poised to grow from USD 54.74 billion in 2022 to USD 124.33 billion by 2030, growing at a CAGR of 10.8% in the forecast period (2023-2030).
Global Precision Immuno-Oncology is an advanced and promising field in cancer treatment, utilizing precise and personalized approaches to target and eradicate cancer cells. By combining immunotherapy with precision medicine, this innovative approach aims to enhance the effectiveness of cancer treatment while minimizing side effects. Cutting-edge technologies, such as next-generation sequencing and biomarker analysis, play a crucial role in identifying specific tumor characteristics and guiding treatment decisions. With ongoing research and clinical trials, Precision Immuno-Oncology holds great potential in revolutionizing cancer care and improving patient outcomes worldwide.
Top-down and bottom-up approaches were used to estimate and validate the size of Precision Immuno-Oncology market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined by using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.
Global Precision Immuno-Oncology Market Segmental Analysis
Precision Immuno-Oncology Market is segmented on the basis of Treatment type, cancer type, end-user, biomarker, and region. By end use, the Precision Immuno-Oncology Market is segmented into hospitals, clinics, research institutes, and others. By cancer type, the Precision Immuno-Oncology Market is segmented into Lung cancer, Breast cancer, Prostate cancer, Melanoma, and others. By treatment type, the Precision Immuno-Oncology Market is segmented into immune checkpoint inhibitors, car T cell therapy, cancer vaccines, and others. By biomarker, the Precision Immuno-Oncology Market is segmented into PD-L1, BRCA, KRAS, EGFR, and others. By region, the Precision Immuno-Oncology Market is segmented into North America, Europe, Asia Pacific, Middle East and Africa, and Latin America.
Driver
The increasing prevalence of cancer is expected to drive the demand for Precision Immuno-Oncology. As cancer cases continue to rise, there is a growing need for more effective and targeted treatment options. Precision Immuno-Oncology offers the potential to tailor cancer therapies to individual patients based on their specific tumor characteristics and immune responses. By harnessing the power of the immune system to fight cancer, this emerging field holds promise in improving treatment outcomes and addressing the challenges posed by various types of cancer.
Restraints
The growth of the Global Precision Immuno-Oncology market is impeded by the significant cost associated with its implementation. The advanced technologies and personalized nature of precision immuno-oncology therapies can be financially challenging for both healthcare providers and patients. The high cost of treatments may limit accessibility and adoption, hindering the market's potential growth. Addressing these cost-related challenges through research, development, and innovative pricing strategies will be crucial to overcome this restraint and unlock the full potential of precision immuno-oncology in cancer treatment.
Market Trends
In precision immuno-oncology treatments is the increasing utilization of combination therapies alongside traditional cancer treatments like chemotherapy and radiation therapy. This approach has gained popularity due to its potential to enhance treatment effectiveness and combat treatment resistance. For instance, the combination of immunotherapy and chemotherapy has shown promising outcomes in treating certain cancer types like lung cancer and melanoma. While chemotherapy reduces tumor size, immunotherapy helps the patient's immune system recognize and attack cancer cells more effectively.
Table of Contents
Executive Summary
- Market Overview
- Wheel of Fortune
Research Methodology
- Information Procurement
- Secondary & Primary Data Sources
- Market Size Estimation
- Market Assumptions & Limitations
Parent Market Analysis
- Market Overview
- Market Size
- Market Dynamics
- Drivers
- Opportunities
- Restraints
- Challenges
Key Market Insights
- Technology Analysis
- Pricing Analysis
- Supply Chain Analysis
- Value Chain Analysis
- Ecosystem of the Market
- IP Analysis
- Trade Analysis
- Startup Analysis
- Raw Material Analysis
- Innovation Matrix
- Pipeline Product Analysis
- Macroeconomic Indicators
- Top Investment Analysis
- Key Success Factor
- Degree of Competition
Market Dynamics & Outlook
- Market Dynamics
- Drivers
- Opportunities
- Restraints
- Challenges
- Regulatory Landscape
- Porters Analysis
- Competitive rivalry
- Threat of Substitute Products
- Bargaining Power of Buyers
- Threat of New Entrants
- Bargaining Power of Suppliers
- Skyquest Special Insights on Future Disruptions
- Political Impact
- Economic Impact
- Social Impact
- Technical Impact
- Environmental Impact
- Legal Impact
Global Precision Immuno-Oncology Market by End use
- Market Overview
- Hospital
- Clinics
- research institutes and others
Global Precision Immuno-Oncology Market by Cancer type
- Market Overview
- Lung cancer
- breast cancer
- prostate cancer
- melanoma and others
Global Precision Immuno-Oncology Market by Treatment type
- Market Overview
- checkpoint inhibitors
- car T cell therapy
- cancer vaccines
- and others
Global Precision Immuno-Oncology Market by Biomarker
- Market Overview
- PD-L1
- BRCA
- KRAS
- EGFR
- and others.
Global Precision Immuno-Oncology Market Size by Region
- Market Overview
- North America
- USA
- Canada
- Europe
- Germany
- Spain
- France
- UK
- Rest of Europe
- Asia Pacific
- China
- India
- Japan
- South Korea
- Rest of Asia-Pacific
- Latin America
- Brazil
- Rest of Latin America
- Middle East & Africa (MEA)
- GCC Countries
- South Africa
- Rest of MEA
Competitive Landscape
- Top 5 Player Comparison
- Market Positioning of Key Players, 2021
- Strategies Adopted by Key Market Players
- Top Winning Strategies
- By Development
- By Company
- By Year
- Recent Activities in the Market
- Key Companies Market Share (%), 2021
Key Company Profiles
- Adaptimmune Therapeutics plc
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Agenus Inc.
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Amgen Inc.
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- AstraZeneca plc
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Bristol Myers Squibb Company
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Celgene Corporation
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Eli Lilly and Company
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- F. Hoffmann-La Roche Ltd.
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Gilead Sciences, Inc.
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- GlaxoSmithKline plc
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Iovance Biotherapeutics, Inc.
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Juno Therapeutics, Inc.
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Kite Pharma, Inc.
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Merck & Co., Inc.
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Neon Therapeutics, Inc.
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Novartis AG
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Pfizer Inc.
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Sanofi SA
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Seattle Genetics, Inc.
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Takeda Pharmaceutical Company Limited
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
